Clinical characteristics, treatment patterns and persistence in individuals with T2D initiating a Glucagon-like-peptide 1 receptor agonists (GLP-1 RA): a retrospective analysis of the Diabetes Prospective Follow-Up (DPV) registry.
Heike JungSascha René TittelNanette C SchlootElke HeitmannThorsten OttoJeremie LebrecMarianne PavelStefanie LanzingerPublished in: Diabetes, obesity & metabolism (2023)
Real-world registry data revealed improved outcomes with longer median GLP-1 RA persistence; ~50% of patients overall achieved HbA1c <7% at 12 months. Persistence was highest with baseline OAD and/or insulin, and tended to increase over the period 2007-2020. This article is protected by copyright. All rights reserved.
Keyphrases
- type diabetes
- end stage renal disease
- rheumatoid arthritis
- glycemic control
- ejection fraction
- newly diagnosed
- cardiovascular disease
- disease activity
- electronic health record
- peritoneal dialysis
- prognostic factors
- single cell
- ankylosing spondylitis
- systemic lupus erythematosus
- adipose tissue
- patient reported outcomes
- combination therapy
- weight loss
- replacement therapy